Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.
/ 43 items
#XY News-Driven Stocks↓
Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.
FDA Delays Popular Nicotine Pouches Over Youth Risks
Popular nicotine pouches like Zyn and Velo remain unapproved in the US despite FDA fast-track. Agency hesitates due to rising youth use and addiction concerns.
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Grifols Plans U.S. IPO for Biopharma Business to Cut Debt and Boost Growth
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.